Skip to main content
  1. Life
  2. Health & Fitness
  3. Healthcare

Libido-boosting female sex drug returns from limbo

See also

A pill that treats low sex drive in women is now back on track for review by the U.S. Food and Drug Administration (FDA), according to a statement by its maker Sprout Pharmaceuticals.

In 2010, the FDA rejected the drug, called flibanserin, saying the it failed to demonstrate safety and effectiveness in treating low sex drive—called hypoactive sexual desire disorder—in pre-menopausal women.

Hypoactive sexual desire disorder (HSDD) is the most commonly reported form of female sexual dysfunction. The condition affects about 10 percent of pre-menopausal women in the U.S., according to a study of flibanserin published in Journal of Sexual Medicine.

HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity. According to the company, the "absence of sexual fantasies and desire" causes distress or interpersonal difficulty.

The cause of HSDD is believed to involve various social, psychological and biological factors.

"In clinical trials, flibanserin has outperformed placebo with statistical significance and, importantly, women treated with flibanserin perceived their improvement to be clinically meaningful," said Cindy Whitehead, president and chief operating officer of Sprout Pharmaceuticals.

"It is true that flibanserin does not cause hypersexuality but by that definition, modest would be what we’re aiming for," said Whitehead.

Flibanserin is a non-hormonal drug similar to antidepressants such as Effexor (venlafaxine) and Wellbutrin (bupropion).

The company claims that flibanserin corrects an imbalance of brain chemicals: Dopamine and norepinephrine (both responsible for sexual excitement) and serotonin (responsible for sexual inhibition).

In studies, flibanserin was tested for its ability to increase the frequency of satisfying sexual events, increase the intensity of sexual desire and decrease the distress women feel from HSDD.

In January, another drug for female sexual health achieved a milestone. Trimel Pharmaceuticals announced it completed enrollment for its ongoing study of Tefina—a nasal spray that contains a low dose of the hormone testosterone.

Tefina is being studied as a treatment for women with female orgasmic disorder (FOD). FOD is the persistent or recurrent delay in, or absence of, orgasm following normal sexual excitement.

As with the makers of flibanserin, the makers of Tefina say that an "absence of orgasm" causes personal distress or interpersonal difficulties.

-- Brett Grodeck



  • Johnny Manziel
    Should Johnny Manziel apologize for his hard partying over the offseason?
    Today's Buzz
  • Crop circles
    Similar crop circles appeared in Germany and England within days of each other
    19 Photos
  • Advanced placement
    The AP program is gaining traction as a key component in college admissions
    5 Photos
  • Beach hats
    Beat the heat with the best summer beach hats for women
    Beach Hats
  • Expectations for ministry
    Pastor preaches to newly ordained ministers about expectations for ministry
    6 Photos
  • Medical symptoms
    See which symptoms should cause you to seek a doctor’s attention right away
    6 Photos

Related Videos:

  • Chagas in US: Deadly 'kissing bug' disease on the rise, doctors warn [Report]
    <div class="video-info" data-id="518343282" data-param-name="playList" data-provider="5min" data-url=""></div>
  • Do you remember more if the memory is personally relevant?
    <div class="video-info" data-id="517368989" data-param-name="playList" data-provider="5min" data-url=""></div>
  • Greenwich Village, tree-lined street
    <div class="video-info" data-id="518343322" data-param-name="playList" data-provider="5min" data-url=""></div>